Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

Phase 3

Completed

Conditions: Agitation
Schizophrenia
Schizo Affective Disorder
Schizoaffective Disorder
Schizophreniform Disorders

Interventions: Drug: Sublingual film containing dexmedetomidine (BXCL501)
Drug: Placebo Film

Brief Summary: This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia. The BXCL501-301 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in agitation associated with schizophrenia, schizoaffective disorder or schizophreniform disorder.

Detailed Description: The study will enroll approximately 375 subjects randomized 1:1:1 to dose regimens of 180µg, 120µg BXCL501, or placebo. Male and female adults with acute agitation associated with schizophrenia, schizoaffective disorder, or schizophreniform disorder will be enrolled. Eligible subjects may be identified in outpatient clinics, mental health, psychiatric or medical emergency services including medical/psychiatric observation units, or as newly admitted to a hospital setting for acute agitation or already in hospital for chronic underlying conditions. Subjects will be domiciled in a clinical research setting or hospitalized to remain under medical supervision while undergoing screening procedures to assess eligibility. Efficacy and safety assessments will be conducted periodically before and after dosing.

Recruitment & Eligibility

Inclusion Criteria

A subject will be eligible for inclusion in the study if he or she meets the following criteria:

Male and female patients between the ages of 18 to 75 years, inclusive.
Patients who have met DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder.
Patients who are judged to be clinically agitated at Screening and Baseline with a total score of ≥ 14 on the 5 items (poor impulse control, tension, hostility, uncooperativeness, and excitement) comprising the PANSS Excited Component (PEC).
Patients who have a score of ≥ 4 on at least 1 of the 5 items on the PEC at Baseline.
Patients who read, understand, and provide written informed consent.
Patients who are in good general health prior to study participation as determined by a detailed medical history, physical examination, 12-lead ECG with rhythm strip, blood chemistry profile, hematology, urinalysis, and in the opinion of the Principal Investigator.
Participants who agree to use a medically acceptable and effective birth control method

Exclusion Criteria

A subject will be excluded from the study if he or she meets the following criteria:

Patients with agitation caused by acute intoxication, including positive identification of alcohol by breathalyzer or drugs of abuse (with the exception of THC) during urine screening.
Use of benzodiazepines, hypnotics and anti-psychotic drugs in the 4 hours before study treatment.
Treatment with alpha-1 noradrenergic blockers (terazosin, doxazosin, tamsulosin, alfuzosin, or prazosin) or other prohibited medications.
Patients who are judged to be at significant risk of suicide
Female patients who have a positive pregnancy test at screening or are breastfeeding.
Patients who have hydrocephalus, seizure disorder, or history of significant head trauma, stroke, transient ischemic attack, subarachnoid bleeding, brain tumor, encephalopathy, meningitis, Parkinson's disease or focal neurological findings.
History of syncope or other syncopal attacks, current evidence of hypovolemia, orthostatic hypotension.
Patients with laboratory or ECG abnormalities considered clinically significant by the investigator.
Patients with serious or unstable medical illnesses.
Patients who have received an investigational drug within 30 days prior to the current agitation episode.
Patients who are considered by the investigator, for any reason, to be an unsuitable candidate for receiving DEX.

Arm && Interventions

Group	Intervention	Description
120 Micrograms	Sublingual film containing dexmedetomidine (BXCL501)	Sublingual film containing 120 Micrograms dexmedetomidine
180 Micrograms	Sublingual film containing dexmedetomidine (BXCL501)	Sublingual film containing 180 Micrograms dexmedetomidine
Placebo	Placebo Film	Sublingual placebo film

Primary Outcome Measures

Name	Time	Method
Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score	Baseline and 2 hours	The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score Over Time	Baseline and 10, 20, 30, 45, 60, 90 minutes post-dose	Effect on agitation onset was measured by change from baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) total score. The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).

Locations (1): BioXcel Clinical Research Site
🇺🇸
Richardson, Texas, United States